Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia | Zendy

Charlotte Bradbury | Zendy; Julie Pell | Zendy; Quentin A. Hill | Zendy; Catherine Bagot | Zendy; Nichola Cooper | Zendy; Jenny Ingram | Zendy; Katie Breheny | Zendy; Rebecca Kandiyali | Zendy; Rachel Rayment | Zendy; Gillian Evans | Zendy; Kate Talks | Zendy; Ian Thomas | Zendy; Rosemary Greenwood | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia

Author(s) -

Charlotte Bradbury,

Julie Pell,

Quentin A. Hill,

Catherine Bagot,

Nichola Cooper,

Jenny Ingram,

Katie Breheny,

Rebecca Kandiyali,

Rachel Rayment,

Gillian Evans,

Kate Talks,

Ian Thomas,

Rosemary Greenwood

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2100596

Subject(s) - medicine , adverse effect , hazard ratio , mycophenolate , glucocorticoid , gastroenterology , randomization , platelet , liter , randomized controlled trial , immune thrombocytopenia , surgery , confidence interval , transplantation

Immune thrombocytopenia is a rare autoimmune disorder with associated bleeding risk and fatigue. Recommended first-line treatment for immune thrombocytopenia is high-dose glucocorticoids, but side effects, variable responses, and high relapse rates are serious drawbacks.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research